Abbott Laboratories Guides FY24 Adj. EPS In Line With Estimates - Update

RTTNews | 279 วันที่ผ่านมา
Abbott Laboratories Guides FY24 Adj. EPS In Line With Estimates - Update

(RTTNews) - While reporting financial results for the fourth quarter on Wednesday, Abbott Laboratories (ABT) initiated earnings and adjusted earnings guidance for the full-year 2024.

For fiscal 2024, the company now projects earnings in a range of $3.20 to $3.40 per share and adjusted earnings in a range of $4.50 to $4.70 per share.

On average, 24 analysts polled by Thomson Reuters expect the company to report earnings of $4.64 per share for the year. Analysts' estimates typically exclude special items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

แท็ก : ABT
read more
Abbott Laboratories Boosts FY24 Earnings Outlook - Update

Abbott Laboratories Boosts FY24 Earnings Outlook - Update

While reporting financial results for the second quarter on Thursday, Abbott Laboratories (ABT) provided earnings and adjusted earnings guidance for the third quarter and raised its outlook for the full-year 2024.
RTTNews | 103 วันที่ผ่านมา
Abbott Laboratories Says FDA Approves Assert-IQ Insertable Cardiac Monitor

Abbott Laboratories Says FDA Approves Assert-IQ Insertable Cardiac Monitor

Abbott Laboratories (ABT) announced Thursday that its Assert-IQ insertable cardiac monitor (ICM) has received U.S. Food and Drug Administration (FDA) clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats.
RTTNews | 530 วันที่ผ่านมา
Abbott Says FDA Approves Spinal Cord Stimulation Devices To Treat Chronic Back Pain

Abbott Says FDA Approves Spinal Cord Stimulation Devices To Treat Chronic Back Pain

Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain.
RTTNews | 532 วันที่ผ่านมา
Abbott Says FDA Oks Proclaim XR Spinal Cord Stimulation System To Treat DPN

Abbott Says FDA Oks Proclaim XR Spinal Cord Stimulation System To Treat DPN

Abbott Laboratories, Inc. (ABT) announced Thursday that the U.S. Food and Drug Administration (FDA) has approved its Proclaim XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes.
RTTNews | 642 วันที่ผ่านมา